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Summary Thirty human lung cancer cell lines were tested for chemosensitivity using the semi-automated,
non-clonogenic MTT assay. The tumour cell lines came from three major categories of patients: untreated
small cell lung cancer (SCLC); SCLC relapsing on chemotherapy; and non-SCLC predominantly from
untreated patients. From these data IC50 values were derived for each drug in each cell line. While some
inter-experimental variability was observed, the rank order of chemosensitivity of each cell line within this
panel was significantly correlated between experiments. These results show that tumour cell lines derived from
untreated small cell lung cancer patients were the most chemosensitive for adriamycin, melphalan, vincristine
and VP16 compared to the other cell types. In addition, untreated SCLC was more sensitive than non-SCLC
to BCNU and cis-platin, while vincristine was the only drug to which treated SCLC was more sensitive
compared to the non-SCLC lines. In contrast, no significant differences between the lung cancer types were
observed for vinblastine. Thus, this panel of lung cancer cells exhibited a drug sensitivity profile paralleling
that observed in clinical practice. These results suggest that this lung cancer cell line panel in combination
with a relatively simple but reproducible chemosensitivity assay, such as the MTT assay, has potential for the
testing of drug combinations and evaluating new anti-cancer agents in vitro.
Human lung cancer is an excellent model for assessing
whether in vitro drug sensitivity or resistance of tumour cells
correlates with clinical sensitivity or resistance. Clinically,
approximately 85% of small cell lung cancer patients are
sensitive to chemotherapy at presentation, although their
tumours almost invariably relapse and become clinically
resistant to chemotherapy (Ihde & Bunn, 1982), with less
than 10% of patients surviving more than 2 years (Johnson
et al., 1985). In contrast, non-small cell lung cancers are
usually clinically resistant to chemotherapy at presentation
(Livingston, 1977). However, with the use of platinum based
drug combinations, such as cis-platin with VP-16, vinblastine
or vindesine, response rates of 40-60% have been reported
(Klastersky et al., 1982; Gralla et al., 1981). We asked the
question, do lung cancer cell lines in vitro have a similar
spectrum of chemosensitivity and resistance, and can differ-
ences be detected using a simple growth assay? To answer
this, we assembled a large panel of human lung cancer cell
lines, including tumour lines derived from untreated small
cell lung cancer patients, small cell lung cancer lines estab-
lished at the time patients' tumours had relapsed after
chemotherapy and thus were clinically defined as drug-
resistant, and a panel of cell lines derived from patients with
non-small cell lung cancer. We began by testing single drugs
that have been used widely in the chemotherapy of lung
cancer including: adriamycin, cis-platin, vinblastine, vincris-
tine and VP-16. In addition, although CCNU is the most
widely used nitrosourea in lung cancer, BCNU was used in
this study as less problems were encountered with solubility.
Melphalan was used as an alkylating agent, as this drug does
not require metabolic activation in contrast to the more
commonly used cytotoxin cyclophosphamide (Friedman et
al., 1979). Chemosensitivity experiments were performed
using reduction of a tetrazolium salt (MTT) as the assessible
end-point (Black & Speer, 1954; Kondo & Ohkubo, 1967).
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This particular assay has been semi-automated by Mossman,
(1983), and further modified by us (Carmichael et al., 1987a)
to allow better solubilization of the formazan product for
absorbance measurements. The MTT assay, as described,
uses microtitre plates and scanning plate readers that mea-
sure absorbance values in individual wells, allowing replicate
testing of several drugs at multiple concentrations on many
tumour cell lines. In tests of chemosensitivity (Carmichael et
al., 1987a) and radiosensitivity (Carmichael et al., 1987b) on
drug sensitive and resistant Chinese hamster cells and 2
human lung cancer cell lines, we found that the MTT assay
gave response curves that were highly correlated with both
clonogenic (Hill, 1983; Hamburger & Salmon, 1977) and dye
exclusion assays (Weisenthal et al., 1983) grown in parallel
(Carmichael et al., 1987a). For any given tumour cell line the
optical density of the solubilized formazan product obtained
after incubating tumour cells with MTT is directly pro-
portional, over a large range, to the number of cells per well
(Carmichael et al., 1987a), making the assay directly compar-
able with assays counting the total number of cells in the
culture before and after a treatment. This assay also has the
advantage that it can be used on virtually all human lung
cancer cell lines, including those difficult to assay using
clonogenicity as the end-point because of low cloning effi-
ciencies, and/or difficulty in preparing viable single cell
suspensions (Bertoncello et al., 1982; Selby et al., 1983).
Finally, the Division of Cancer Treatment, National Cancer
Institute, USA, is currently evaluating this assay using panels
of human tumour cell lines to screen for new drugs. Our
data give a positive answer to the question about correlation
of in vitro chemosensitivity and resistance of human lung
cancer cells and in doing so provide a basis for the use of
panels of human tumour cell lines to screen for new drugs.
Materials and methods
Cell lines
Exponentially growing cultures were maintained in a humidi-
fied atmosphere of 7% CO2/93% air at 37°C. Apart from 2
cell lines, all were established at the NCI-Navy Medical
Oncology Branch. These cell lines had been established over
a 10 year period, all cell lines having been in culture for a
minimum of 6 months. Passage number at the time of
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experiments ranged from 20 to 100 for the various cell lines.
All cell lines were grown in RPMI 1640 medium (GIBCO)
supplemented with 10% foetal bovine serum, penicillin and
streptomycin. The lung cancer cell lines used and their
histologic type, together with details of patient treatment
status are listed in Table I.
Small cell lung cancer Fifteen small cell lung cancer cell
lines were utilized, all originating from patients with a
histological diagnosis of small cell lung cancer. Seven were
derived from previously untreated patients, of which 2
exhibited the variant phenotype (Carney et al., 1985; Gazdar
et al., 1985). The remaining 8 cell lines were derived from
previously treated patients, of whom 3 showed variant
characteristics (Carney et al., 1985; Gazdar et al., 1985). All
cell lines grew as floating aggregates, apart from NCI-H841
which grew as a loosely adherent monolayer.
Non-small cell lung cancer Fifteen non-small cell lines were
used, all of which grew in monolayer culture. These lines
comprised 5 adenocarcinomas, 3 adenosquamous, 2 squa-
mous, 3 large cell, and 2 mesothelioma cell lines. One of
these cell lines, NCI-H661, was derived from a patient who
had received chemotherapy prior to the establishment of the
line. Ten cell lines were derived from previously untreated
patients, with no information available on the treatment
status of the remaining patients from whom cell lines were
established.
MTT assay
A modification of the method described by Mossman (1983)
was used. Cell suspensions were obtained from exponentially
growing cultures of each cell line by trypsinization of the
non-small cell lung cancer lines plus NCI-H841, and
repeated pipetting of the small cell lung cancer cell lines.
Cells were plated in 180up1 medium at the appropriate
seeding density into 96 well microtitre plates. In preliminary
experiments, seeding densities were determined for each cell
line ensuring that cultures did not become confluent before
conducting the assay. Cell number per microtitre well was
proportional to the absorbance of the solubilized formazan
Table I Characteristics and MTT assay plating densities of lung cancer cell lines
Lung cancer Histological Patient treatment Patient Cells plated
cell line type status response per well (x 103)
NCI-H 60 C-SCLC CMC-VAP PR 10
NCI-H 69 C-SCLC CMC-VAP CR 10
NCI-H 82 V-SCLC CMC-VAP CR 5
NCI-H128 C-SCLC CMC-VAP PR 10
NCI-H146 C-SCLC CMC-VAP PR 10
NCI-H187 C-SCLC (CAPO) (PR) 20
NCI-H209 C-SCLC U/T - 20
NCI-H249 C-SCLC HD MTX NR 10
NCI-N417 V-SCLC U/T 5
NCI-H524 V-SCLC CMC-VAP PR 10
NCI-H526 V-SCLC (CMC-VAP) (NR) 20
NCI-H678 C-SCLC (VP/PLAT) (CR) 20
NCI-H719 C-SCLC (VP/PLAT) (CR) 20
NCI-H841 V-SCLC CMC-VAP; VP/PLAT NR 5
NCI-H889 C-SCLC (VP/PLAT) (CR) 10
NCI-H 23 Adenocarcinoma U/T - 2.5
NCI-H125 Adenocarcinoma U/T - 5
NCI-H157 LCC U/T - 10
NCI-H226 Squamous U/T - 5
NCI-H290 Mesothelioma U/T - 5
NCI-H322 Adenosquamous U/T - 2.5
NCI-H358 Adenocarcinoma U/T - 2.5
NCI-H460 LCC U/T - 1.0
NCI-H520 Squamous U/T - 10
NCI-H522 Adenocarcinoma U/T - 2.5
NCI-H596 Adenosquamous XRT - 5
NCI-H647 Adenosquamous XRT - 2.5
NCI-H661 LCC VP/PLAT NR 2.5
A549 Adenocarcinoma U/K 1.0
JMN Mesothelioma U/K 2.5
Histological type: The histological type of the tumour specimen taken from the patient and the
tumour cell line were similar except in 3 instances. NCI-H226 was scored as a mesothelioma in the
patient but appears as a poorly differentiated squamous carcionoma in culture. Lines NCI-H322 and
NCI-H358 were both scored as bronchioloalveolar carcinomas in the patient, but after culture,
both in nude mice and in cell culture the former appears as an adenosquamous carcinoma, whilst
the latter appears as an adenocarcinoma. NCI-H460 appeared as a poorly differentiated large cell
carcinoma in the patient and after culture. It expresses some neuroendocrine properties but appears
quite different from the appearance of variant small cell lung cancers. Patient treatment status:
small cell lung cancer specimens were harvested at the time of relapse from patients treated with the
following regimes: CMC-VAP (Cohen et al., 1979) represents alternating combinations of cyclo-
phosphamide, methotrexate and CCNU (CMC) and vincristine, adriamycin and procarbazine
(VAP). CAPO (Brower et al., 1983) represents combination chemotherapy with cyclophosphamide,
adriamycin, VP-16 and vincristine. VP/plat represents treatment with VP-16 and cis-platin which
has been shown to be effective in the treatment of small cell lung cancer (Sierocki et al., 1979) and
HD MIX indicates treatment with high dose methotrexate as a single agent. The patient's response
to this treatment is shown in the next column, with CR representing a complete response to
therapy, PR a partial response and NR no response. Regimes and responses in parenthesis
represent the effect of treatment in patients subsequently exposed to cytotoxic drugs, in whom the
cell line was established prior to exposure to drugs. U/T: Untreated; U/K: Unknown. Cell line
details previously described in Carney et al. (1985) and Gazdar et al. (1985).
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(Carmichael et al., 1987a). To each well 20p1 of 10 x drug in
PBS was added, with PBS added to control wells. Cells were
incubated with or without drug for 4 days, allowing suffi-
cient time for cell replication, drug induced cell death, and
loss of enzymic activity, which generates the formazan
product from the MTT substrate (Mossman, 1983). Following
a 4 day incubation, 100 g MTT (50,u1 2mgml-P solution
was added to each well, and the plates incubated for 4h.
The microtitre plates were centrifuged at 450g for 10min,
220Il supernatant removed using a Costar-96 Transpipette
system, leaving -30 l residual medium in each well. MTT
formazan crystals were then resolubilized by adding 150p1
100% dimethylsulfoxide (DMSO) to each well. Plates were
then agitated on a plate shaker for 5min, following which
spectrophotometric absorbance at 540nm was immediately
determined using a scanning multiwell spectrophotometer
(Biotek Instruments Inc., Burlington, Vermont).
Drugs
Drugs were obtained as formulated for clinical use, except
for melphalan and BCNU, which were obtained from
Sigma Chemical Co., St Louis, MO. All drugs were
prepared freshly for each experiment at 100 x the maximal
final concentration used. Melphalan was dissolved in acid
ethanol and BCNU was dissolved in 50% ethanol, while the
remaining drugs were dissolved in normal saline or water.
All drugs were subsequently diluted using PBS and finally
passed through a 0.45 um sterile filter (Millipore Corporation,
Bedford, MA) prior to use.
Statistical methods and study design
Datum points in Figures 1 and 2 represent the mean of
octuplicate tests at each drug concentration + s.d. Data in
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Tables II and III represent the mean IC50±+s.d. of up to 3
experiments. For certain cell lines there was only one
satisfactory experiment and the IC50 is given without a
standard deviation. Tables IV and V were done using
the Spearman rank order analysis, taking into account
Bonferroni criteria for the assessment of significance of
multiple tests. Variation between histological sub-groups of
lung cancer for each drug was analysed using the Kruskal-
Wallis one way analysis of variance (Table VI) and indivi-
dual groups were tested using the Mann-Whitney test (Table
VII). All 30 cell lines were tested simultaneously, and the
experiment repeated 3 times. Controls included media alone,
media plus drug and an untreated cellular control. Each
drug was tested at 10 drug concentrations with each concen-
tration point representative of 8 replicate wells for each
cell line. Graphs were prepared manually, with response
curves generated using a best fit of the data. Response
curves were plotted for all drugs, with the IC50 values for
each cell line determined graphically as the dose of drug
causing a 50% reduction in absorbance compared with
control values. Statistical calculations were performed using
microcomputer programs (Statworks and Cricketgraph,
Cricket Software, Philadelphia, PA).
Results
Lung cancer cell lines and plating densities
Table I lists the characteristics of the 30 lung cancer cell lines
used in this study including histologic type, prior therapy,
and response to therapy. The small cell lines nearly all grow
as floating aggregates, while the non-small cell lung cancers
grow as attached monolayers. In addition to their morpho-
logic and biochemical differences (Carney et al., 1985;
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Figure 1 Cell survival 4 days after plating and drug exposure measured by the MTT assay for adriamycin, BCNU, cis-platin and
melphalan for 3 different lung cancer cell lines. NCI-H209, untreated small cell lung, (U): NCI-H146, treated small cell lung
cancer, (O): NCI-H322 non-small cell lung cancer, (A). The datum points shown on each figure represent the mean +s.d. for the 8
replicate determinations normalized to the control value which was set at 100%.
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Figure 2 Cell survival 4 days after plating and drug exposure
measured by the MTT assay for VP-16, vinblastine and vincris-
tine for 3 lung cancer cell lines. Cell lines and symbols are the
same as for Figure 1. Datum points are the mean +s.d. for the 8
replicate determinations normalized to the control value set at
100%.
Gazdar et al., 1985), the lung cancer cell lines vary widely in
their growth rates and cloning efficiencies. Thus, preliminary
experiments were done to determine the optimal seeding
density required for each cell line to be in the log phase of
growth when the assay was terminated 4 days after plating
(Table I). The mean absorbance for the control (untreated)
wells for all 30 cell lines in the assays reported was 0.35,
with a standard deviation of 0.12 between the different cell
lines. For any one cell line, the standard deviation of control
absorbance values among the 8 replicates was <20%.
Effect of drugs on killing lung cancer cells in the MTT
assay
Tumour cell killing as a function of drug concentration was
determined for the 7 drugs, using all 30 cell lines, and this
was repeated in 3 experiments. The drugs were tested over
the following concentration ranges: adriamycin 1-500 nM;
BCNU 5-1000 pM; cis-platin 0.1-30 uM; melphalan 0.01-
500 pM; vinblastine 0.1-100 nM; vincristine 0.1-100 nM and
VP-16 0.1-100 IM. These concentration ranges gave 50% or
greater reduction in the production of formazan product for
the 30 cell lines allowing the determination of an IC50 for
each drug with each cell line. However, 2 cell lines, NCI-
H125 and NCI-HI57, were highly resistant to vinblastine,
and determination of an IC50 was not possible. One example
from each of the 3 main treatment/histologic types
(untreated SCLC, treated SCLC and non-SCLC) for each of
the 7 drugs used are shown in Figures 1 and 2. The slopes of
the dose-response curves varied considerably with the drugs
used, as shown in Figures 1 and 2. Steep dose-response
curves are seen with cis-platin and BCNU, whereas in
contrast, shallow dose response curves are observed with VP-
16 and vinblastine. Table II (for small cell lines) and Table
III (for non-small cell lines) summarize the IC50 data for all
30 cell lines.
Reproducibility of the chemosensitivity profile of the lung
cancer cell line panel
When repeated dose-response curves were generated for cell
lines within each experiment, the IC50 values varied by
approximately 15%. However, wider variations in IC50
values were seen between experiments. We noted that the
differences between experiments affected all of the cell lines
tested for a particular drug and presumably represent factors
we do not currently know how to control. However, the
large standard deviations may be explained, in part, by the
wide dosage range covered by each drug in this study. It was
important to determine if the relative degree of chemo-
sensitivity or resistance among the 30 cell lines for each drug
was maintained between experiments. Thus, for each drug
tested, we asked did the tumour cell lines retain their rank
order of chemosensitivity relative to other members of the
lung cancer cell line panel between experiments? To do this
we performed a rank order analysis of the IC50s for each
drug as determined in separate experiments (Table IV). This
analysis shows a highly significant correlation between
experiments for the rank order of chemosensitivity of the
tumour cell lines for all 7 drugs.
Correlation of chemosensitivity between drugs for the lung
cancer panel
We then asked if rank order of sensitivity to one drug
predicted rank order of sensitivity to other drugs. As is
shown in Table V, rank order of sensitivity to certain drugs
was highly correlated with sensitivity to many of the agents
tested. Whether this is a manifestation of the multidrug
resistance phenotype (Ling et al., 1983) remains to be
determined. Of interest, vinblastine sensitivity was only signi-
ficantly correlated with vincristine sensitivity, while cis-platin
and VP-16 rank order of chemosensitivities were not signifi-
cantly correlated (Table V).
Comparisons of chemosensitivity among different lung cancer
groups
We then asked if relative rank order of chemosensitivity to
each drug was associated with the major clinical status
groups, namely untreated small cell lung cancer, relapsed
small cell lung cancer and non-small cell lung cancer. First,
the Kruskal-Wallis one way analysis of variance was used to
analyze the data from all 30 cell lines for each drug, to
assess whether any significant differences between histologic
or treatment groups could be detected (Table VI). This test
is a non-parametric analysis based on the ranks of the
dependant variable (IC50) for the 3 lung cancer treatment/
histologic classes), compared to the independent variable
(drug). Highly significant differences in chemosensitivity were
observed between lung cancer sub-groups for adriamycin,
melphalan, vincristine and VP-16, while no significant differ-
ences were detected for BCNU, cis-platin and vinblastine.
We then performed Mann-Whitney comparisons of
untreated SCLC vs. treated SCLC and vs. non-SCLC, and
compared treated SCLC vs. non-SCLC for rank order of
sensitivity to each drug (Table VII). In all cases the signifi-
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Table II Mean IC50 values of small cell lung cancer lines +s.d. determined from the survival curves of 3 replicate experiments
(nM) (jiM) (jM) (pM) (nM) (nM) (#M)
Cell line Adriamycin BCNU Cis-platin Melphalan Vinblastine Vincristine VP-16
Untreated Classic
NCI-H187 25.5 (22) 35.8 (32) 1.0 (0.5) 1.8 (2) 4.0 (2) 0.8 (0.6) 0.6 (0.5)
NCI-H209 24.8 (7.2) 35.8 (19) 0.3 (0.3) 0.2 (0.1) 3.3 (3) 0.3 (0.1) 0.5 (0.2)
NCI-H678 61.0 NE 3.4 (2.3) 6.3 (8) NE NE 0.40
NCI-H719 10.1 (7.7) 128 (56) 3.8 (1.1) 0.1 2.8 NE 0.31 (0.2)
NCI-H889 13.4 (6.5) NE 1.7 (1.6) 3.6 (2) 1.75 1.6 (0.8) 0.6 (0.6)
Untreated Variant
NCI-H417 12.9 (3) 74.6 (16) 2.0 (1.3) 0.8 8.1 (4.7) 2.2 (1.4) 3.7 (2)
NCI-H526 37.0 (17) 30.8 (25) 0.7 (0.4) 0.1 (0) 3.7 (2.7) 0.8 (0.7) 1.2 (1)
Treated Classic
NCI-H60 171 (134) 36.0 (24) 1.4 (0.3) 2.8 (2.9) 4.8 (5.4) 1.4 (1.4) 5.5 (3.8)
NCI-H69 127 (46) 103 (51) 2.0 (1) 10.1 (4) 5.0 (4.0) 2.4 (0.7) 18.3 (10)
NCI-H128 110 (126) 78.5 (53) 4.8 (0) 20.8 (8) 4.4 (2.8) 4.9 (3.7) 25.7 (27)
NCI-H146 144 (86) 95 (13) 3.7 (1) 13.8 (8) 10.6 (0) 3.9 (1.6) 2.9 (3)
NCI-H249 127 (123) 75.9 (21) 1.5 (0) 10.2 (11) 3.6 (3.3) 1.0 (0.2) 4.0 (3)
Treated Variant
NCI-H82 94.0 (71) 104 (51) 1.1 (0) 7.9 (6.2) 3.4 (1.9) 1.7 (0.4) 10.5 (14)
NCI-H524 15.8 (3.9) 43.6 (13) 0.4 (0) 2.8 (2.4) 1.8 (1.7) 1.0 (0.5) 1.4 (0.3)
NCI-H841 231.0 (162) 162 (29) 21.0 (8.8) 84.0 (23) 5.9 (5) 7.2 (5) 9.7 (6.1)
Mean IC50 values for 7 drugs using 15 small cell lung cancer cell lines. IC50 values are shown with the standard deviation in brackets.
Where no bracket is shown, the IC50 value is representative of one experiment only and NE represents no evaluable experiments.
Table III Mean IC50 values of non-small cell lung cancer cell lines +s.d. determined from the survival curve of 3 replicate experiments
(nM) (pM) (#M) (pM) (nM) (nM) (PM)
Cell line Adriamycin BCNU Cis-platin Melphalan Vinblastine Vincristine VP-16
Adenocarcinoma
NCI-H23 38.7 (26) 112.0 2.5 (2.5) 8.7 (7) 5.2 2.2 (1.3) 1.3
NCI-H125 216.0 (58) 96.4 (52) 1.5 (0.7) 8.2 (3) >100 1.9 (1.3) 5.9 (3.7)
NCI-H358 85.0 (56) 76.3 (9) 5.9 (1.7) 31.0 (9) 16.0 (14) 8.1 (2.6) 10.3 (9)
NCI-H522 197.0 (72) NE 3.2 (2.0) 30.3 (18) 3.1 (3.0) 1.2 (0.6) 11.3 (1)
A549 57.7 (32) 97.3 (6) 1.5 (1.3) 11.4 (7) 4.4 (4.6) 13.7 (11) 1.9 (0.6)
Squamous
NCI-H226 221 (90) 162 (30) 2.9 (2.0) 56.3 (17) 19.0 (10) 22.9 (24) 5.2 (0.5)
NCI-H520 411 (132) 117 (20) 3.4 (1.9) 23.3 (9) 3.2 (1.7) 5.9 (3.6) 40.9 (22)
Adenosquamous
NCI-H596 813 (207) 221 (15) 9.1 (13) 60.7 (30) 20.4 (13) 16.8 (20) 79.0 (15)
NCI-H647 115 (10) 118 (112) 10.4 (10) 55.3 (32) 3.2 (1.8) 6.5 (3.3) 7.3 (7)
NCI-H322 173 (165) 206 (123) 10.2 (4) 75.5 (51) 3.8 (3.9) 4.9 (2.2) 23.9 (30)
Large Cell Carcinoma
NCI-H157 238 (167) 151 (55) 16.8 (3) 104.8 (60) >100 115.0 (53) 30.5 (13)
NCI-H460 16.5 (8) 45.2 (10) 1.7 (2) 1.6 (0.4) 6.2 3.5 (3.2) 0.5 (1.1)
NCI-H661 130 (57) 102.8 (42) 4.4 (3) 20.4 (19) 1.8 (0.6) 1.5 (1.2) 1.0
Mesothelioma
NCI-H290 26.8 (14) 51.7 (8) 1.0 (0.4) 3.7 (0.6) 3.5 (3.4) 2.3 (2.1) 3.0 (0.1)
JMN 40.2 (13) 36.8 (10) 2.3 (2.3) 3.3 (1) 9.2 (3.7) 11.4 (8.2) 1.7 (0.2)
Mean ICo values for 7 drugs using 15 non-small cell lines. IC50 values are shown with the standard deviation in brackets. Where no
bracket is shown, the IC50 value is representative of one experiment only and NE represents no evaluable experiments.
cant differences discovered by the Kruskal-Wallis test
resulted from the lower IC50 values for the untreated SCLC
and their consequent ranking as the most sensitive cells. In
addition, a significant difference for vincristine was found
between treated SCLC and non-SCLC (Table VII).
Discussion
In our previous work, we have shown the MTT assay to
correlate extremely well with clonogenic and dye exclusion
assays in generating response curves for both cytotoxic drugs
and radiation (Carmichael et al., 1987a,b). The drugs tested
in these studies included adriamycin, cis-platin, melphalan,
vincristine and VP-16. The current study applied this semi-
automated assay to a detailed study of a much larger panel
of 30 lung cancer cell lines, using 7 drugs (or their close
relatives) commonly used in the treatment of lung cancer.
The results show that:
1. Based on their relative IC50 values, a reproducible rank
order for chemosensitivity could be generated in the 30
line panel for each of the 7 drugs.
2. Small cell lung cancer lines derived from untreated
patients had a significantly different rank order of
sensitivity (were the most sensitive) to adriamycin,
melphalan, vincristine and VP-16 compared to treated
SCLC and non-SCLC, and were significantly more
sensitive to BCNU and cis-platin when compared to
non-SCLC.
3. The only significant difference between treated SCLC
and non-SCLC was toward the drug vincristine.
4. No significant differences were observed between the 3
treatment/histologic groups for vinblastine.CHEMOSENSITIVITY TESTING OF LUNG CANCER CELL LINES 545
Table IV Spearman rank order analysis of relative drug sensitivity
of lung cancer cell lines
No. ofpaired Spearman Significance
Drug observations correlation (P value)
Adriamycin 16 0.923 0.0000003
BCNU 18 0.676 0.002
Cis-platin 11 0.884 0.0003
Melphalan 12 0.914 0.00003
Vinblastine 11 0.752 0.0076*
Vincristine 13 0.874 0.00001
VP-16 11 0.818 0.002
In independent experiments performed over a period of 3 months
the IC50s of the tumour cell lines were redetermined and the rank
order of tumour cell sensitivity recalculated. Spearman correlation
values (rho) and their significance were determined using the
Statworks microcomputer program. Vinblastine: In repeat experi-
ments Spearman correlations of 0.715 and 0.854 with significance
values of P=0.0013 and 0.0008 respectively were obtained indicating
significant correlation of the rank order of chemosensitivity for this
drug.
*Note that a P value of <0.002 for 21 individual tests is
equivalent to P<0.05 for a single test by Bonferroni criteria.
Table V Spearman rank order analysis of relative drug sensitivity
of lung cancer cell lines to different drugs
All cell lines
Specimen
correlation Significance
Drugs (rho) (P value)
Adriamycin vs. BCNU 0.619 0.001
Adriamycin vs. cis-platin 0.529 0.003a
Adriamysin vs. melphalan 0.813 4.55 x 10-8
Adriamysin vs. vinblastine 0.383 0.04a
Adriamycin vs. vincristine 0.475 0.01la
Adriamycin vs. VP-16 0.757 1.26 x 10-6
BCNU vs. cis-platin 0.763 3.57 x 10-6
BCNU vs. melphalan 0.750 6.66 x 106
BCNU vs. vinblastine 0.165 0.41
BCNU vs. vincristine 0.658 0.00026
BCNU vs. VP-16 0.561 0.0023
Cis-platin vs. melphalan 0.754 1.47 x 10-6
Cis-platin vs. vinblastine 0.266 0.163a
Cis-platin vs. vincristine 0.708 2.45 x 10-5
Cis-platin vs. VP-16 0.459 0.01
Melphalan vs. vinblastine 0.288 0.13a
Melphalan vs. vincristine 0.688 5.05 x 10-5
Melphalan vs. VP-16 0.738 3.24 x 10-6
Vinblastine vs. vincristine 0.581 0.001
Vinblastine vs. VP-16 0.324 0.086a
Vincristine vs. VP-16 0.522 0.0044a
aNote that a P value of <0.002 for 21 individual tests is
equivalent to P<0.005 for a single test by Bonferroni criteria.
Table VI Kruskal-Wallis one way analysis of
variance comparing three major subgroups of lung
cancer
Signifcance
H-statistic (P value)
Adriamycin 11.029 0.004
BCNU 5.37 0.068
Cis-platin 4.031 0.133
Melphalan 12.804 0.002
Vinblastine 2.893 0.235
Vincristine 10.411 0.005
VP-16 17.193 0.004
5. There was significant correlation of sensitivity and
resistance between certain drugs (particularly adriamy-
cin, melphalan and vincristine).
6. Vinblastine sensitivity was correlated only with vincris-
tine sensitivity.
7. Sensitivity to cis-platin and VP-16 were not correlated.
Variation was observed between experiments, although the
cause of this remains uncertain. A number of factors may
have contributed including the wide dose ranges of drugs
used in these studies. Also, for some drugs, the dose
response curves were extremely shallow, making precise
definition of the IC50 difficult. Despite variation of the IC50
values to different drugs of up to one log for the same cell
line assayed at different times, we found the relative rank
order of sensitivities of the 30 cell lines for any one drug to
be highly correlated between assays. In view of this varia-
tion, it will be essential to include previously tested lung
cancer cell lines of varying sensitivities to serve as reference
points for subsequent assays, particularly for the testing of
new anti-cancer drugs.
The MTT assay offers many advantages, as it is per-
formed in microtitre plates with the production of a col-
oured formazan product. The simplicity of the assay permits
the testing of multiple replicates and conditions with record-
ing of results using commercially available ELISA plate
readers. In fact, this paper summarizes data from over
40,000 test points. Other advantages of the assay include the
low intratest variation between data points (+15%s.d.) and
the ability to test tumour cell lines with low cloning efficien-
cies or cell lines from which it may be difficult to generate
single cell suspensions (Bertoncello et al., 1982; Selby et al.,
1983). Currently, the limiting feature of this assay is data
analysis that obviously requires the use of appropriate
computer software, which is now becoming generally
available.
Testing of primary tumour samples using both clonogenic
(Hamburger & Salmon, 1977; Salmon et al., 1980; Van Hoff
et al., 1981) and other assays (Weisenthal et al., 1983; Bird et
al., 1985; Van Hoff et al., 1985) has been shown to be a
good predictor of the in vivo response in individual patients.
The MTT assay, as described, would be unable to accom-
plish this as non-tumour cells also reduce the substrate. The
assay requires a population of tumour cells free of normal
cells and would fail to detect killing effects that were only
expressed in a small sub-population of cells (such as effects
only registered in clonogenic cells). We know that both
human and Chinese hamster lung fibroblast cells reduce
MTT. However, there is no further documented evidence for
normal tissues reducing MTT. However, the use of tumour
cell lines provides pure populations of tumour cells, and our
previous work has shown a good correlation between results
of the MTT and the clonogenic assays for the drugs tested in
this report. Other workers using smaller numbers ofcell lines
and different assays have also concluded that there is a
correlation between the clinical response of certain tumour
types and the in vitro response using established cell lines of
similar histology (Hill, 1983; Cole, 1986). In contrast to our
finding that untreated SCLC lines were more sensitive than
previously treated SCLC lines, Hug et al. (1984) found no
differences in the chemosensitivity patterns of treated versus
untreated breast cancer lines. The possibility exists that some
of the differences observed in this study could be due to
morphological differences, i.e., floating versus monolayer
cells. However, this difference is unlikely to be of signifi-
cance as a significant difference was observed between
previously treated and untreated small cell lung cancer cells,
virtually all of which grew as floating aggregates. Likewise,
differences in growth rate were unlikely to be of significance,
as the untreated small cell lines which had the longest
doubling time were in fact the most sensitive.
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Table VII Mann-Whitney rank order analysis of the three different classes of
lung cancer lines
Untreated SCLC Untreated SCLC Treated SCLC
vs. VS. vs.
Drug tested treated SCLC non-SCLC non-SCLC
P value (one tailed)a
Adriamycin <0.005 <0.005 Not significant
BCNU Not significant <0.025 Not significant
Cis-platin Not significant <0.05 Not significant
Melphalan <0.005 <0.005 Not significant
Vinblastine Not significant Not significant Not significant
Vincristine <0.05 <0.005 <0.05
VP-16 <0.005 <0.005 Not significant
aThe rank order of all 3 major classes were compared. The question was asked
whether the untreated SCLC lines had lower IC50 ratings for each drug, while the
same question was asked for the treated SCLC vs. the non-SCLC lines. In two
tailed tests, all of the comparisons significant at the <0.005 level in one tailed
tests are significant at <0.01, those significant at the <0.025 level are significant
at the <0.05 level, while those significant at the <0.05 level have a P value of
<0.1. As suggested by Cricket software, statistical tables (Goldstein, 1964) were
used to determine the P values for the Mann-Whitney U statistic generated.
applications or corollaries. In these studies we have concen-
trated on drugs actually used in clinical treatment, whenever
possible, such as adriamycin, cis-platin, vincristine and VP-
16, or similar classes of drug to those more frequently used
such as BCNU and melphalan. It was of interest to see that
cis-platin and VP-16 sensitivity patterns were different, and
that the 3 lung cancer treatment groups did not differ
significantly with respect to cis-platin sensitivity. The combi-
nation of cis-platin and a vinca alkaloid appears to be active
against both small cell (Hug et al., 1984) and non-small cell
lung cancer (Gralla et al., 1981). In addition, only one of the
treated small cell lines (NCI-H841) came from a patient
whose tumour had relapsed on cis-platin and VP-16 combi-
nation chemotherapy, and this line had the highest IC50
value for cis-platin.
There are many potential ways for analysing the data
obtained from these studies. Different inhibitory concen-
tration points such as the IC50, IC70 or IC90 could be used,
or area under the curve of drug concentrations, as well as
utilizing different incubation times. Our major findings are
that a panel of lung cancer cell lines can be rank ordered as
to relative chemosensitivity and that this correlates with
histologic type and prior therapy status. While we have
emphasized the three major groups, each contains subgroups
as well, such as classic and variant SCLC, and several non-
SCLC histologic subtypes. In these groups there are excep-
tions with a treated SCLC line (NCI-H524) and a non-SCLC
line (NCI-H460) both sensitive to many drugs. However,
clinical experience shows that the occasional relapsed SCLC
or non-SCLC patient proves to be sensitive to chemother-
apy, while the occasional untreated SCLC can be resistant to
therapy. Prospective clinical trials which we are now con-
ducting are aimed at clarifying the relationship between in
vitro and clinical responses in individual patients. Neverthe-
less, the results reported here should support and encourage
the use of the combination of the semi-automated MTT
assay and the panel of lung cancer cell lines to begin clinical
in vitro correlations of drug sensitivity and resistance.
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